Literature DB >> 25040257

Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.

Dominika Borek1, Maciej Kozak, Jimin Pei, Mariusz Jaskolski.   

Abstract

The periplasmic enzyme l-asparaginase type II from Escherichia coli (EcAII) converts l-asparagine to l-aspartate and ammonia. EcAII is an important drug in the treatment of childhood acute lymphoblastic leukemia, the most common malignancy in children. Leukemic blast cells lack the ability to synthesize l-asparagine and rely on other sources of l-asparagine for protein synthesis. EcAII injections deplete extracellular levels of l-asparagine, disrupting protein synthesis and inducing apoptosis in the malignant cells. The detailed mechanism of l-asparaginase catalytic action, the molecular mechanisms of its anticancer activity and the side effects associated with the treatment, including resistance to therapy, are not fully understood despite over 40 years of research. Here, we present X-ray structures of EcAII with an active site mutation, D90E, in three crystal forms. The region of the mutation is well ordered, allowing precise functional analysis of the consequences of the replacement of Asp90. In all three structures, the mutant protein exhibits an open conformation of the active site. In one of the structures, a zinc cation has been detected. The zinc cation is coordinated in a region of the protein that is implicated in the immunological response to EcAII treatment. A combined sequence-structure analysis of bacterial-type l-asparaginases reveals that the metal coordination may play a role in the response to asparaginase treatment. The observation of a zinc-binding site in antileukemic l-asparaginases provides new insight, with consequences for acute lymphoblastic leukemia therapy. DATABASES: The atomic coordinates of the monoclinic, orthorhombic and trigonal forms of the D90E mutant of Escherichia coli type II asparaginase have been deposited with the RCSB PDB with accession codes 1JAZ, 1JJA and 1IHD, respectively. ENZYMES: EC 3.5.1.1, l-asparagine amidohydrolase, l-asparaginase; EC 3.5.1.38, l-glutamine (l-asparagine) amidohydrolase, glutaminase-asparaginase; EC 6.3.5.6, l-aspartyl-tRNA(Asn) : l-glutamine amido-ligase (ADP-forming), asparaginyl-tRNA synthase (glutamine-hydrolysing).
© 2014 FEBS.

Entities:  

Keywords:  acute lymphoblastic leukemia; l-asparaginase; mutation; pancreatitis; zinc-binding site

Mesh:

Substances:

Year:  2014        PMID: 25040257     DOI: 10.1111/febs.12906

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  11 in total

1.  Introduction: celebrating the international year of crystallography: introduction.

Authors:  Mariusz Jaskolski; Alexander Wlodawer
Journal:  FEBS J       Date:  2014-09       Impact factor: 5.542

Review 2.  The role of zinc and its compounds in leukemia.

Authors:  Alexey P Orlov; Marina A Orlova; Tatiana P Trofimova; Stepan N Kalmykov; Dmitry A Kuznetsov
Journal:  J Biol Inorg Chem       Date:  2018-02-28       Impact factor: 3.358

3.  Recombinant L-asparaginase 1 from Saccharomyces cerevisiae: an allosteric enzyme with antineoplastic activity.

Authors:  Iris Munhoz Costa; Leonardo Schultz; Beatriz de Araujo Bianchi Pedra; Mariana Silva Moreira Leite; Sandra H P Farsky; Marcos Antonio de Oliveira; Adalberto Pessoa; Gisele Monteiro
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

4.  The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity.

Authors:  Hien Anh Nguyen; Donald L Durden; Arnon Lavie
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

5.  Opportunistic complexes of E. coli L-asparaginases with citrate anions.

Authors:  Jacek Lubkowski; Waikin Chan; Alexander Wlodawer
Journal:  Sci Rep       Date:  2019-07-30       Impact factor: 4.379

6.  Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).

Authors:  Noeman Ardalan; Abbas Akhavan Sepahi; Ramazan Ali Khavari-Nejad
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

7.  Crystal structures of the elusive Rhizobium etli L-asparaginase reveal a peculiar active site.

Authors:  Joanna I Loch; Barbara Imiolczyk; Joanna Sliwiak; Anna Wantuch; Magdalena Bejger; Miroslaw Gilski; Mariusz Jaskolski
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

Review 8.  Structural and biophysical aspects of l-asparaginases: a growing family with amazing diversity.

Authors:  Joanna I Loch; Mariusz Jaskolski
Journal:  IUCrJ       Date:  2021-06-30       Impact factor: 4.769

9.  Improving the Treatment of Acute Lymphoblastic Leukemia.

Authors:  Ashish Radadiya; Wen Zhu; Adriana Coricello; Stefano Alcaro; Nigel G J Richards
Journal:  Biochemistry       Date:  2020-08-23       Impact factor: 3.162

Review 10.  Molecular Analysis of L-Asparaginases for Clarification of the Mechanism of Action and Optimization of Pharmacological Functions.

Authors:  Marina V Pokrovskaya; Vadim S Pokrovsky; Svetlana S Aleksandrova; Nikolay N Sokolov; Dmitry D Zhdanov
Journal:  Pharmaceutics       Date:  2022-03-09       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.